Cyclacel Pharmaceuticals IncFind Ratings Reports
CYCLACEL PHARMACEUTICALS's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CYCLACEL PHARMACEUTICALS is extremely liquid. Currently, the Quick Ratio is 3.89 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 19.37% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||0.0||0.14|
|Net Income ($mil)||-1.56||-3.04|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||12.73||17.12|
|Total Assets ($mil)||17.07||21.46|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||0.0||-2663.31|
|Return on Assets||-60.35||-58.11|
|Return on Equity||-81.95||-79.7|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||4.27||2.97|
|Div / share||0.0||0.0|
|Book value / share||3.0||5.36|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||208672.0||808991.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.57 indicates a significant discount versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYCLACEL PHARMACEUTICALS proves to trade at a discount to investment alternatives within the industry.
|CYCC NM||Peers 44.01||CYCC NM||Peers 43.69|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYCC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYCC's P/CF is negative making the measure meaningless.
|CYCC NM||Peers 27.93||CYCC NA||Peers 0.55|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CYCC's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYCC 0.57||Peers 11.44||CYCC 33.79||Peers -7.96|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYCC is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CYCC is expected to have an earnings growth rate that significantly exceeds its peers.
|CYCC 10.44||Peers 190.63||CYCC -55.19||Peers 434.91|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYCC is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYCC significantly trails its peers on the basis of sales growth